Recursion Pharmaceuticals combines artificial intelligence, automation, and biotechnology research across multiple ...
Recursion has stumbled through an early test of its tech-enabled approach to drug discovery, reporting a hit on its phase 2 primary endpoint of safety and tolerability but failing to wow on the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results